➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
AstraZeneca
Dow
Merck
Johnson and Johnson

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HIZENTRA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for HIZENTRA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01354587 Evaluation of Efficacy and Tolerability of Hizentra® Unknown status University of South Florida N/A 2010-10-01 The purpose of this study is to measure the changes in the Treatment Satisfaction Questionnaire for Medication in the areas of effectiveness, side effects, and convenience of administration of each medication in Primary Immunodeficiency Disorder (PIDD) subjects transitioning from subcutaneous Vivaglobin® to Hizentra®.
NCT01828294 Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis Terminated CSL Behring N/A 2011-10-01 The study is being done with patients with Myasthenia Gravis (MG), age 18-80 years, positive acetylcholine receptor antibody, receiving greater than 30mg of prednisone daily. Patients may or may not be receiving anticholinesterase agents. A common treatment for patients with this disease includes the administration of intravenous immunoglobulin (IVIG), which is a plasma protein that is given to help maintain adequate antibody levels to prevent infections and decrease the symptoms of the disease of Myasthenia Gravis. This study is being done to test if giving this medication in a subcutaneous form (into the fat of the abdomen, legs and thighs) will be better tolerated for patients with Myasthenia Gravis.
NCT01828294 Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis Terminated St. Louis University N/A 2011-10-01 The study is being done with patients with Myasthenia Gravis (MG), age 18-80 years, positive acetylcholine receptor antibody, receiving greater than 30mg of prednisone daily. Patients may or may not be receiving anticholinesterase agents. A common treatment for patients with this disease includes the administration of intravenous immunoglobulin (IVIG), which is a plasma protein that is given to help maintain adequate antibody levels to prevent infections and decrease the symptoms of the disease of Myasthenia Gravis. This study is being done to test if giving this medication in a subcutaneous form (into the fat of the abdomen, legs and thighs) will be better tolerated for patients with Myasthenia Gravis.
NCT02100969 Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis Recruiting CSL Behring Phase 2 2015-01-01 The purpose of this study is to determine whether Hizentra is a safe and effective treatment for people with myasthenia gravis (MG).
NCT02100969 Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis Recruiting Mazen Dimachkie, MD Phase 2 2015-01-01 The purpose of this study is to determine whether Hizentra is a safe and effective treatment for people with myasthenia gravis (MG).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for HIZENTRA

Condition Name

Condition Name for HIZENTRA
Intervention Trials
Myasthenia Gravis 3
Dermatomyositis 2
Chronic Inflammatory Demyelinating Polyneuropathy 2
Multifocal Motor Neuropathy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for HIZENTRA
Intervention Trials
Immunologic Deficiency Syndromes 3
Myasthenia Gravis 3
Muscle Weakness 2
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for HIZENTRA

Trials by Country

Trials by Country for HIZENTRA
Location Trials
United States 10
Canada 3
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for HIZENTRA
Location Trials
Florida 2
Pennsylvania 1
Texas 1
New York 1
Kansas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for HIZENTRA

Clinical Trial Phase

Clinical Trial Phase for HIZENTRA
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for HIZENTRA
Clinical Trial Phase Trials
Recruiting 6
Not yet recruiting 2
Terminated 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for HIZENTRA

Sponsor Name

Sponsor Name for HIZENTRA
Sponsor Trials
CSL Behring 7
University of South Florida 2
Thomas Jefferson University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for HIZENTRA
Sponsor Trials
Other 11
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
McKesson
Merck
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.